Phillip J. Koo, MD, presented “Use of Radiopharmaceuticals: Updates on Ongoing Clinical Trials” during the 19th Annual Future Directions in Urology Symposium on August 11, 2018 in Colorado Springs, Colorado.
How to cite:Koo, Phillip, J. “Use of Radiopharmaceuticals: Updates on Ongoing Clinical Trials” August 11, 2018. Accessed [date today]. https://grandroundsinurology.com/use-of-radiopharmaceuticals-updates-on-ongoing-clinical-trials/
Use of Radiopharmaceuticals: Updates on Ongoing Clinical Trials– Summary:
Phillip J. Koo, MD, provides a brief update of recent approvals and ongoing trials in in imaging, therapeutic, and theranostic radiopharmaceutical agents, such fluciclovine, radium-223, and lutetium-177.
Radiopharmaceuticals for Imaging in Prostate Cancer
Radiology not only detects the presence of disease and morphologic information, but also serves further utilities. New radiologic analytic tools can provide advanced analyses, such as treatment response and characterize disease. For example, fluciclovine (brand name Axumin) is a newly available tool that greatly improves physicians’ ability to detect disease. The OSPREY trial is currently observing a prostate-specific membrane antigen (PSMA) agent for imaging in prostate cancer. Hopefully, the results of this trial will lead to a more widespread availability of PSMA.
In general, it is important for members of the radiology and urologic oncology community to define when and why to image disease and how imaging affects patient outcomes.
Therapeutic Radiopharmaceuticals
Radium-223 has seen significant developments in recent years. Notably, this radiotherapy has seen changes in its European Medicines Agency (EMA) label. Likely, radium-223 will have changes in its FDA label in the near future, as well. The ongoing ERA 223 trial currently shows that patients receiving radium-223 have increases in fractures compared to the placebo arm. However, further updates from this trial will show more definitive conclusions.
Theranostic Agents
The multisite, prospective trial, VISION, is currently observing the theranostic PSMA agent lutetium-177 in metastatic castration-resistant prostate cancer (mCRPC). Provided that results are favorable, this trial may lead to FDA approval of lutetium-177, and possibly better access to the drug for patients worldwide. Additionally, the TheraP trial is comparing lutetium-177 to cabazitaxel in mCRPC.
About Dr. Koo
Dr. Koo is the Division Chief of Radiology at Banner MD Anderson Cancer Center in Phoenix, Arizona. He is extremely accomplished and knowledgeable in the field of radiology and nuclear medicine.
About the Future Directions in Urology Symposium
The Future Directions in Urology Symposium (FDUS) is an annual collaborative meeting with a faculty consisting of the top researchers, physicians, and educators in the field of urology. During FDUS, experts provide updates on recent developments and debate innovative management approaches in genitourinary cancers and urologic conditions. Subsequently, the experts devise consensus statements in accordance with the discussions held in the meeting.
In this video, Dr. Koo discloses the thesis of the discussion he led during FDUS.
ABOUT THE AUTHOR
Phillip J. Koo, MD, is the Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine in Aurora, Colorado. He completed his fellowship at the Harvard Medical School Joint Program in Nuclear Medicine in Boston, Massachusetts. Dr. Koo is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine(ABNM).
